SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices
Cryoport, Inc. (NASDAQ: CYRX) and SK pharmteco have announced a strategic collaboration to provide integrated logistics and manufacturing services for biotechnology and pharmaceutical companies. Cryoport will support SK pharmteco's contract manufacturing of small molecule and cell and gene therapy products with its end-to-end supply chain services, including shipping systems, data solutions, and bioservices.
Jerrell Shelton, CEO of Cryoport, expressed enthusiasm about the partnership, highlighting its alignment with Cryoport's goal to diversify revenue streams, particularly from commercial cell and gene therapies. Dana Cipriano, VP of Analytical Services at SK pharmteco, emphasized the importance of supply chain safety and integrity in the growing cell and gene therapy industry, reaffirming their commitment to providing high-quality services tailored to customer and patient needs.
Cryoport, Inc. (NASDAQ: CYRX) e SK pharmteco hanno annunciato una collaborazione strategica per fornire servizi integrati di logistica e produzione per le aziende biotech e farmaceutiche. Cryoport supporterà la produzione su contratto di piccoli molecole e prodotti per la terapia cellulare e genica di SK pharmteco con i suoi servizi end-to-end di fornitura, che includono sistemi di spedizione, soluzioni dati e bioservizi.
Jerrell Shelton, CEO di Cryoport, ha espresso entusiasmo per la partnership, evidenziando la sua coerenza con l'obiettivo di Cryoport di diversificare le fonti di reddito, in particolare da terapie cellulari e geniche commerciali. Dana Cipriano, VP dei Servizi Analitici di SK pharmteco, ha sottolineato l'importanza della sicurezza e dell'integrità della catena di fornitura nell'emergente industria della terapia cellulare e genica, ribadendo il loro impegno a fornire servizi di alta qualità su misura per le esigenze dei clienti e dei pazienti.
Cryoport, Inc. (NASDAQ: CYRX) y SK pharmteco han anunciado una colaboración estratégica para proporcionar servicios integrados de logística y fabricación para empresas de biotecnología y farmacéuticas. Cryoport apoyará la fabricación por contrato de pequeñas moléculas y productos de terapia celular y génica de SK pharmteco con sus servicios de cadena de suministro de extremo a extremo, que incluyen sistemas de envío, soluciones de datos y bioservicios.
Jerrell Shelton, CEO de Cryoport, expresó su entusiasmo por la asociación, destacando su alineación con el objetivo de Cryoport de diversificar las fuentes de ingresos, particularmente en terapias celulares y génicas comerciales. Dana Cipriano, VP de Servicios Analíticos en SK pharmteco, enfatizó la importancia de la seguridad e integridad de la cadena de suministro en la creciente industria de las terapias celulares y génicas, reafirmando su compromiso de ofrecer servicios de alta calidad adaptados a las necesidades de los clientes y pacientes.
Cryoport, Inc. (NASDAQ: CYRX)와 SK pharmteco가 생명공학 및 제약 회사를 위한 통합 물류 및 제조 서비스를 제공하는 전략적 협력을 발표했습니다. Cryoport는 SK pharmteco의 소분자 및 세포 및 유전자 요법 제품 계약 제조를 지원하며, 배송 시스템, 데이터 솔루션 및 생물 서비스를 포함한 종합적인 공급망 서비스를 제공합니다.
Cryoport의 CEO인 Jerrell Shelton은 파트너십에 대한 기대감을 표명하며, 상업적인 세포 및 유전자 요법 쪽으로 수익원을 다양화하겠다는 Cryoport의 목표와의 일치점을 강조했습니다. SK pharmteco의 분석 서비스 부사장인 Dana Cipriano는 성장하는 세포 및 유전자 요법 산업에서 공급망의 안전성과 무결성의 중요성을 강조하며 고객과 환자의 요구에 맞춘 고품질 서비스를 제공하겠다는 약속을 재확인했습니다.
Cryoport, Inc. (NASDAQ: CYRX) et SK pharmteco ont annoncé une collaboration stratégique pour fournir des services de logistique et de fabrication intégrés aux entreprises biopharmaceutiques et pharmaceutiques. Cryoport soutiendra la fabrication sous contrat de petites molécules et de produits de thérapie cellulaire et génique par SK pharmteco grâce à ses services de chaîne d'approvisionnement de bout en bout, y compris des systèmes d'expédition, des solutions de données et des bioservices.
Jerrell Shelton, PDG de Cryoport, a exprimé son enthousiasme pour ce partenariat, soulignant son alignement avec l'objectif de Cryoport de diversifier ses sources de revenus, notamment pour les thérapies cellulaires et géniques commerciales. Dana Cipriano, VP des Services Analytiques chez SK pharmteco, a souligné l'importance de la sécurité et de l'intégrité de la chaîne d'approvisionnement dans l'industrie en pleine croissance de la thérapie cellulaire et génique, réaffirmant leur engagement à fournir des services de haute qualité adaptés aux besoins des clients et des patients.
Cryoport, Inc. (NASDAQ: CYRX) und SK pharmteco haben eine strategische Zusammenarbeit bekannt gegeben, um integrierte Logistik- und Fertigungsdienstleistungen für Biotechnologie- und Pharmaunternehmen bereitzustellen. Cryoport wird die Vertragsfertigung von kleinen Molekülen und Zell- und Gentherapieprodukten von SK pharmteco mit seinen End-to-End-Lieferkettenservices unterstützen, die Versandlösungen, Datendienstleistungen und Biologiedienste umfassen.
Jerrell Shelton, CEO von Cryoport, äußerte Begeisterung über die Partnerschaft und hob hervor, dass sie mit Cryoports Ziel übereinstimmt, Einnahmequellen zu diversifizieren, insbesondere aus kommerziellen Zell- und Gentherapien. Dana Cipriano, VP der analytischen Dienstleistungen bei SK pharmteco, betonte die Bedeutung von Sicherheit und Integrität in der Lieferkette in der wachsenden Industrie der Zell- und Gentherapien und bekräftigte ihr Engagement, hochqualitative Dienstleistungen anzubieten, die auf die Bedürfnisse von Kunden und Patienten zugeschnitten sind.
- Strategic collaboration with SK pharmteco expands Cryoport's market reach
- Potential for increased revenue from commercial cell and gene therapies
- Diversification of revenue streams through integrated logistics and manufacturing services
- None.
Insights
This partnership between Cryoport and SK pharmteco is a significant development in the cell and gene therapy logistics sector. By combining Cryoport's end-to-end supply chain solutions with SK pharmteco's manufacturing capabilities, they're creating a more integrated and efficient service for biotech and pharma companies.
The collaboration addresses a critical need in the rapidly growing cell and gene therapy market, where maintaining product integrity throughout the supply chain is paramount. For Cryoport, this deal represents an opportunity to diversify revenue streams and potentially increase its market share in commercial cell and gene therapy support.
From an investor's perspective, this partnership could lead to:
- Increased revenue potential for Cryoport as it taps into SK pharmteco's client base
- Enhanced competitive positioning in the cell and gene therapy logistics market
- Potential for long-term growth as the cell and gene therapy sector expands
However, the impact on short-term financials may be , as such partnerships often take time to fully materialize. Investors should monitor how quickly this collaboration translates into tangible revenue growth for Cryoport.
The strategic collaboration between Cryoport and SK pharmteco is a noteworthy development in the cell and gene therapy (CGT) ecosystem. This partnership addresses a important aspect of CGT development and commercialization: the seamless integration of manufacturing and logistics.
Key points for investors to consider:
- Market Growth: The CGT sector is experiencing substantial growth, with an increasing number of therapies in clinical trials and approaching commercialization.
- Supply Chain Complexity: CGTs require specialized handling and temperature-controlled logistics, which Cryoport excels in providing.
- Competitive Advantage: This integrated offering could attract more biotech clients, potentially giving both companies an edge in a competitive market.
The partnership may lead to accelerated development timelines for CGT products, reducing time-to-market and potentially increasing the success rate of clinical trials. For Cryoport, this could mean a more stable and diversified revenue stream as it supports more commercial-stage therapies.
Investors should watch for indicators of increased client acquisition and retention rates for both companies as a result of this collaboration.
Cryoport, with its ability to provide end-to-end cell and gene therapy support services from biomaterial collection to final delivery via its fully integrated supply chain services and equipment, including its shipping systems, data solutions, and bioservices, will now support SK pharmteco's contract manufacturing of both small molecule and cell and gene therapy products.
"We are delighted to be selected by SK pharmteco in supporting its manufacture of APIs and intermediates, biopharmaceuticals, and cell and gene therapies," said Jerrell Shelton, CEO of Cryoport. "Our organizations share a mission to support the life sciences by helping bring lifesaving treatments to patients. This relationship not only extends our reach to more people in need but also aligns with Cryoport's strategic goal to further diversify and enhance our revenue streams, particularly as we continue to drive higher revenue from the support of commercial cell and gene therapies."
Dana Cipriano, Vice President, Analytical Services for SK pharmteco, added, "The cell and gene therapy industry continues to see substantial growth, and ensuring the safety and integrity of the supply chain is essential for these products. We are dedicated to our clients, and partnering with Cryoport reflects our commitment to providing the highest-quality services that are specifically tailored to meet the needs of our customers and the patients they serve."
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the
For more information about SK pharmteco, please visit www.skpharmteco.com.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the support of SK pharmteco's contract manufacturing of both small molecule and cell and gene therapy products, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sk-pharmteco-and-cryoport-partner-for-cell-and-gene-therapy-logistics-and-bioservices-302258047.html
SOURCE Cryoport, Inc.
FAQ
What is the purpose of the partnership between Cryoport (CYRX) and SK pharmteco?
How will Cryoport (CYRX) support SK pharmteco in this collaboration?
What strategic goal does this partnership align with for Cryoport (CYRX)?
Why is supply chain integrity important in the cell and gene therapy industry according to SK pharmteco?
